Clinical Trials Logo

Malaria, Falciparum clinical trials

View clinical trials related to Malaria, Falciparum.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04280692 Suspended - Malaria,Falciparum Clinical Trials

Controlled Human Malaria Infection Transmission Model - Phase A

CHMI-TransMod
Start date: August 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is to develop a model to test the efficacy of vaccines and/or drugs designed to block transmission of malaria to mosquitoes and to identify the targets of transmission-blocking immunity to malaria.

NCT ID: NCT01849640 Suspended - Clinical trials for Uncomplicated Plasmodium Falciparum Malaria

Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity

Start date: December 2012
Phase: N/A
Study type: Interventional

This is a two-arm, open label Treatment Study comparing the efficacy, safety, tolerability and pharmacokinetics of a three-day course of Dihydroartemisinin-Piperaquine (DP) with or without single-dose primaquine in patients with uncomplicated Plasmodium falciparum malaria. On the last day of DP therapy, volunteers will be randomized to receive either a single 45 mg dose of primaquine (PQ) or DP treatment only (no primaquine).

NCT ID: NCT00616304 Suspended - Clinical trials for Severe Falciparum Malaria

Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria

ARGISM
Start date: February 2008
Phase: Phase 2
Study type: Interventional

Background: Mortality from severe malaria remains ~15% despite the use of the most rapidly parasiticidal antimalarial therapy, artesunate. Adjunctive treatments may improve outcome. Our overall goal is to determine if adjunctive treatment with L-arginine is safe and improves outcomes in severe malaria. In studies to date, we have shown that L-arginine is safe in moderately severe malaria, increases nitric oxide production and improves endothelial function. We now propose to extend these studies to patients with severe malaria. Aims: To determine the safety, preliminary efficacy, pharmacokinetics and pharmacodynamics of L-arginine infusion in severe malaria. Hypothesis: L-arginine will improve endothelial function, lactate clearance time and tissue oxygen delivery compared to saline with no clinically significant adverse effects. Methods: Based on previous pharmacokinetic modeling and simulations, we propose a phase 2A randomised controlled trial of L-arginine vs saline in severe malaria, each given over 8 hours. If safety is demonstrated this will be followed by a phase 2B open-label study of 24-hour infusion of L-arginine in severe malaria with safety and preliminary efficacy compared with the 8 hour infusions given in phase 2A. The primary outcomes will be the improvement in endothelial function and lactate clearance in patients given L-arginine infusion compared with those who received saline. Among the secondary outcomes will be safety and the effect of L-arginine vs saline on tissue oxygen delivery (NIRS). Data from both phase 2A and 2B will be used to generate a pharmacokinetic/ pharmacodynamic model.